Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold

Chemical Biology and Drug Design

Volumn 76, Issue 3, 2010, Pages 269-276

  Hernández Campos, Alicia ^a   Velázquez Martínez, Israel ^a   Castillo, Rafael ^a   López Vallejo, Fabian ^b   Jia, Ping ^c   Yu, Yongping ^c   Giulianotti, Marc A ^b   Medina Franco, Jose L ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

AKT; cancer; drug design; structure activity relationships

Indexed keywords

PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITOR INTERACTION; MOLECULAR DOCKING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955260857     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01002.x     Document Type: Article

References (22)

1. Hennessy B.T., Smith D.L., Ram P.T., Lu Y.L., Mills G.B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discovery 4 : 988 1004.
2. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., Nicosia S.V. (2005) The AKT/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 : 7482 7492.
3. Cheng G.Z., Park S., Shu S.K., He L.L., Kong W., Zhang W.Z., Yuan Z.Q., Wang L.H., Cheng J.Q. (2008) Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8 : 2 6.
4. Lindsley C.W., Barnett S.F., Layton M.E., Bilodeau M.T. (2008) The PI3K/AKT pathway: recent progress in the development of ATP-competitive and allosteric AKT kinase inhibitors. Curr Cancer Drug Targets 8 : 7 18.
5. Kumar C.C., Madison V. (2005) AKT crystal structure and AKT-specific inhibitors. Oncogene 24 : 7493 7501.
6. Mahadevan D., Powis G., Mash E.A., George B., Gokhale V.M., Zhang S.X., Shakalya K. et al. (2008) Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 7 : 2621 2632.
7. Heerding D.A., Rhodes N., Leber J.D., Clark T.J., Keenan R.M., Lafrance L.V., Li M. et al. (2008) Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)- 1-ethyl-7-[(3S)-3-piperidinylmethyl]oxy-1H-imidazo[4,5-c]pyridin-4-yl) -2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem 51 : 5663 5679.
8. Collins I., Caldwell J., Fonseca T., Donald A., Bavetsias V., Hunter L.-J.K., Garrett M.D. et al. (2006) Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. Bioorg Med Chem 14 : 1255 1273.
9. Reuveni H., Livnah N., Geiger T., Kleid S., Ohne O., Cohen I., Benhar M., Gellerman G., Levitzki A. (2002) Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41 : 10304 10314.
10. Saxty G., Woodhead S.J., Berdini V., Davies T.G., Verdonk M.L., Wyatt P.G., Boyle R.G., Barford D., Downham R., Garrett M.D., Carr R.A. (2007) Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem 50 : 2293 2296.
11. Luo Y., Shoemaker A.R., Liu X.S., Woods K.W., Thomas S.A., de Jong R., Han E.K. et al. (2005) Potent and selective inhibitors of AKT kinases slow the progress of tumors in vivo. Mol Cancer Ther 4 : 977 986.
12. Rouse M.B., Seefeld M.A., Leber J.D., McNulty K.C., Sun L., Miller W.H., Zhang S., Minthorn E.A., Concha N.O., Choudhry A.E., Schaber M.D., Heerding D.A. (2009) Aminofurazans as potent inhibitors of AKT kinase. Bioorg Med Chem Lett 19 : 1508 1511.
13. Medina-Franco J.L., Giulianotti M.A., Yu Y., Shen L., Yao L., Singh N. (2009) Discovery of a novel protein kinase B inhibitor by structure-based virtual screening. Bioorg Med Chem Lett 19 : 4634 4638.
14. Singh N., Dueñas-González A., Lyko F., Medina-Franco J.L. (2009) Molecular modeling and dynamics studies of hydralazine with human DNA methyltransferase 1. ChemMedChem 4 : 792 799.
15. Kuck D., Singh N., Lyko F., Medina-Franco J.L. (2010) Novel and Selective DNA Methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg Med Chem 18 : 822 829.
16. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The Protein Data Bank. Nucleic Acids Res 28 : 235 242.
17. Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz D.T. (2006) Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49 : 6177 6196.
18. Sherman W., Day T., Jacobson M.P., Friesner R.A., Farid R. (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49 : 534 553.
19. Medina-Franco J.L., Martinez-Mayorga K., Giulianotti M.A., Houghten R.A., Pinilla C. (2008) Visualization of the chemical space in drug discovery. Curr Comput Aided Drug Des 4 : 322 333.
20. Liu T.Q., Lin Y.M., Wen X., Jorissen R.N., Gilson M.K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35 : D198 D201.
21. Singh N., Guha R., Giulianotti M.A., Pinilla C., Houghten R.A., Medina-Franco J.L. (2009) Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and Molecular Libraries Small Molecule Repository. J Chem Inf Model 49 : 1010 1024.
22. Morphy R. (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53 : 1413 1437.